JP2008526973A - 標的治療薬を作製する方法 - Google Patents

標的治療薬を作製する方法 Download PDF

Info

Publication number
JP2008526973A
JP2008526973A JP2007551343A JP2007551343A JP2008526973A JP 2008526973 A JP2008526973 A JP 2008526973A JP 2007551343 A JP2007551343 A JP 2007551343A JP 2007551343 A JP2007551343 A JP 2007551343A JP 2008526973 A JP2008526973 A JP 2008526973A
Authority
JP
Japan
Prior art keywords
mrna
protein
disease
therapeutic agent
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007551343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526973A5 (https=
Inventor
リチャード ビー． ウィリアムズ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteonova Inc
Original Assignee
Proteonova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteonova Inc filed Critical Proteonova Inc
Publication of JP2008526973A publication Critical patent/JP2008526973A/ja
Publication of JP2008526973A5 publication Critical patent/JP2008526973A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007551343A 2005-01-12 2006-01-12 標的治療薬を作製する方法 Pending JP2008526973A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64319105P 2005-01-12 2005-01-12
PCT/US2006/000956 WO2006076417A1 (en) 2005-01-12 2006-01-12 Method for making targeted therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013028521A Division JP2013138674A (ja) 2005-01-12 2013-02-18 標的治療薬を作製する方法

Publications (2)

Publication Number Publication Date
JP2008526973A true JP2008526973A (ja) 2008-07-24
JP2008526973A5 JP2008526973A5 (https=) 2009-04-16

Family

ID=36677960

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2007551343A Pending JP2008526973A (ja) 2005-01-12 2006-01-12 標的治療薬を作製する方法
JP2013028521A Pending JP2013138674A (ja) 2005-01-12 2013-02-18 標的治療薬を作製する方法
JP2015013910A Pending JP2015091871A (ja) 2005-01-12 2015-01-28 標的治療薬を作製する方法
JP2016243972A Pending JP2017061564A (ja) 2005-01-12 2016-12-16 標的治療薬を作製する方法
JP2018230241A Pending JP2019055991A (ja) 2005-01-12 2018-12-07 標的治療薬を作製する方法
JP2021004884A Pending JP2021063132A (ja) 2005-01-12 2021-01-15 標的治療薬を作製する方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2013028521A Pending JP2013138674A (ja) 2005-01-12 2013-02-18 標的治療薬を作製する方法
JP2015013910A Pending JP2015091871A (ja) 2005-01-12 2015-01-28 標的治療薬を作製する方法
JP2016243972A Pending JP2017061564A (ja) 2005-01-12 2016-12-16 標的治療薬を作製する方法
JP2018230241A Pending JP2019055991A (ja) 2005-01-12 2018-12-07 標的治療薬を作製する方法
JP2021004884A Pending JP2021063132A (ja) 2005-01-12 2021-01-15 標的治療薬を作製する方法

Country Status (4)

Country Link
US (2) US20080199499A1 (https=)
EP (3) EP3431503A1 (https=)
JP (6) JP2008526973A (https=)
WO (1) WO2006076417A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080199499A1 (en) * 2005-01-12 2008-08-21 Proteonova, Inc. Method for Making Targeted Therapeutic Agents
WO2011053730A1 (en) * 2009-10-30 2011-05-05 Proteonova Method for making targeted therapeutic agents directed to soluble targets
US10206998B2 (en) 2005-01-12 2019-02-19 Proteonova, Inc. Modular targeted therapeutic agents and methods of making same
EP2118344B1 (en) * 2007-02-12 2014-07-23 Proteonova, Inc. GENERATION OF LIBRARY OF SOLUBLE RANDOM POLYPEPTIDES LINKED TO mRNA
WO2010051215A1 (en) * 2008-10-31 2010-05-06 Proteonova, Inc. Methods for making hiv vaccines and related compositions
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
PL2971038T3 (pl) 2013-03-14 2020-04-30 Research Corporation Technologies, Inc. Cząsteczki rybotoksyny pochodzące z sarcyny i inne powiązane grzybowe rybotoksyny

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513281A (ja) * 1997-01-21 2002-05-08 ザ ジェネラル ホスピタル コーポレーション Ｒｎａ−蛋白質の融合体を用いた蛋白質の選抜
WO2003044194A1 (en) * 2001-11-16 2003-05-30 Proteonova, Inc. Selection and evolution of nucleic acids and polypeptides
JP2003533995A (ja) * 2000-05-19 2003-11-18 リチャード、 ビー． ウィリアムズ、 核酸およびコードされたポリペプチドのｉｎｖｉｔｒｏでの展開

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661347A (en) * 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
US4882423A (en) * 1984-10-02 1989-11-21 Calpis Food Industry Substance-conjugated complement component C1q
US5837485A (en) * 1988-05-18 1998-11-17 Dr. Karl Tomae Gmbh DNA encoding and biosynthetic process for the preparation of chemical compounds, lantibiotics
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
DE69519929T2 (de) 1994-07-11 2001-05-23 Board Of Regents, The University Of Texas System Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
JPH10505241A (ja) * 1994-09-08 1998-05-26 イムトラン・リミテッド 改変タンパク質
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DK1196637T3 (da) 1999-07-27 2007-07-30 Adnexus Therapeutics Inc Peptidacceptor-ligeringsmetoder
US20030059827A1 (en) * 2001-03-13 2003-03-27 Cayetano Gonzalez Engineered protein binding domains and methods and systems for their design and use
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2471532A1 (en) 2001-10-23 2003-05-01 Centre For Translational Research In Cancer A synthetic chimeric fusion protein with immuno-therapeutic uses
BRPI0315295C1 (pt) * 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
GB0227644D0 (en) 2002-11-27 2003-01-08 Cancer Rec Tech Ltd Specific binding members and uses thereof
CA2512974A1 (en) * 2003-01-13 2004-07-29 Macrogenics, Inc. Soluble fc.gamma.r fusion proteins and methods of use thereof
FI115035B (fi) * 2003-05-02 2005-02-28 Ctt Cancer Targeting Tech Oy In vivo -kuvantaminen käyttäen peptidijohdannaisia
JP2008516586A (ja) 2004-09-30 2008-05-22 メダレックス インコーポレーティッド Ｆｃγ受容体ＩＩ（ＣＤ３２）に対するヒトモノクローナル抗体
US20080199499A1 (en) 2005-01-12 2008-08-21 Proteonova, Inc. Method for Making Targeted Therapeutic Agents
US20080253958A1 (en) * 2006-11-15 2008-10-16 Mccracken Colin G Production of high-purity titanium monoxide and capacitor production therefrom
CA2697612A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513281A (ja) * 1997-01-21 2002-05-08 ザ ジェネラル ホスピタル コーポレーション Ｒｎａ−蛋白質の融合体を用いた蛋白質の選抜
JP2003533995A (ja) * 2000-05-19 2003-11-18 リチャード、 ビー． ウィリアムズ、 核酸およびコードされたポリペプチドのｉｎｖｉｔｒｏでの展開
WO2003044194A1 (en) * 2001-11-16 2003-05-30 Proteonova, Inc. Selection and evolution of nucleic acids and polypeptides

Also Published As

Publication number Publication date
US20110212114A1 (en) 2011-09-01
JP2017061564A (ja) 2017-03-30
JP2015091871A (ja) 2015-05-14
EP2261257B1 (en) 2018-07-11
US20080199499A1 (en) 2008-08-21
EP1846432A1 (en) 2007-10-24
EP3431503A1 (en) 2019-01-23
US9193795B2 (en) 2015-11-24
EP2261257A1 (en) 2010-12-15
EP1846432A4 (en) 2008-11-19
JP2013138674A (ja) 2013-07-18
WO2006076417A1 (en) 2006-07-20
JP2021063132A (ja) 2021-04-22
JP2019055991A (ja) 2019-04-11

Similar Documents

Publication Publication Date Title
JP2019055991A (ja) 標的治療薬を作製する方法
ES2595091T3 (es) Composiciones farmacéuticas con resistencia a CEA soluble
ES2752025T3 (es) Métodos de cribado de proteínas
EP1603941B1 (en) Inhibitors of extracellular hsp90
US9068987B2 (en) Inhibitors of extracellular HSP90
US20090215175A1 (en) Modulation of the poliovirus receptor function
JP2011505795A (ja) バリアントｎｆｋｂｉｂの癌関連エピトープに対する抗体およびその使用
JP2005533794A (ja) アプタマー−毒素分子およびこれを使用する方法
Lu et al. Retrospective analysis of the preparation and application of immunotherapy in cancer treatment
CN118524852A (zh) 治疗或抑制心血管疾病的方法
US20240016927A1 (en) Modular targeted therapeutic agents and methods of making same
JP2007513631A (ja) 核酸およびポリペプチドを選択する系ならびに方法
AU2005221470B2 (en) Inhibitors of extracellular hsp90
WO2025006452A2 (en) NEU5GC-LEWISa-TARGETING MOLECULES AND USES THEREOF IN CANCER
JP2026023561A (ja) Ｖｓｉｇ２に特異的に結合する物質を含む癌の治療剤
Casey et al. Cambridge Healthtech Institute’s 4th Annual Recombinant Antibodies Conference

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120613

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130218

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20130218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130312

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130419

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140409